Found that the treatment of multiple myeloma drug Revlimid latest efficacy
Revlimid (lenalidomide) developed by Celgene Corporation for the treatment of fatal blood diseases. Recently, Celgene Corporation, said, found that the treatment of multiple myeloma drug Revlimid latest efficacy, according to the survey, received a stem cell transplant in patients with multiple myeloma after treatment with Revlimid, can reduce the risk of relapse of 58%. This finding is significant, because the latest experimental results further confirm Revlimid can be used as maintenance therapy drug, and are applicable to those who have previously used other medications or had undergone stem cell transplant patients.
Previously, Revlimid and dexamethasone have been approved for use, treatment for at least one drug was used over multiple myeloma patients. The latest research project by the Cancer and Leukemia Group B (CALGB) conducted, the researchers obtained from experimental data and safety monitoring results showed that patients in the fight against disease progression after treatment effects reached statistical aspects of a significant level.
Earlier this month, Celgene also announced a experimental data show that the single standard drugs (melphalan and prednisone) compared to using Revlimid + standard drug Revlimid after the turn of treatment alone in delaying disease progression aspects of the effect is more good.
If Revlimid can be used as maintenance therapy in the treatment of multiple myeloma, and is approved as first-line treatment of the disease drug, the sales expected to grow from $ 1.7 billion this year, up from 2013's $ 3.6 billion. Some foreign analysts expect, Revlimid sales will boost treatment for multiple myeloma drug market growth.
Found that the treatment of multiple myeloma drug Revlimid latest efficacy
ReplyDeleteRevlimid (lenalidomide) developed by Celgene Corporation for the treatment of fatal blood diseases. Recently, Celgene Corporation, said, found that the treatment of multiple myeloma drug Revlimid latest efficacy, according to the survey, received a stem cell transplant in patients with multiple myeloma after treatment with Revlimid, can reduce the risk of relapse of 58%. This finding is significant, because the latest experimental results further confirm Revlimid can be used as maintenance therapy drug, and are applicable to those who have previously used other medications or had undergone stem cell transplant patients.
Previously, Revlimid and dexamethasone have been approved for use, treatment for at least one drug was used over multiple myeloma patients. The latest research project by the Cancer and Leukemia Group B (CALGB) conducted, the researchers obtained from experimental data and safety monitoring results showed that patients in the fight against disease progression after treatment effects reached statistical aspects of a significant level.
Earlier this month, Celgene also announced a experimental data show that the single standard drugs (melphalan and prednisone) compared to using Revlimid + standard drug Revlimid after the turn of treatment alone in delaying disease progression aspects of the effect is more good.
If Revlimid can be used as maintenance therapy in the treatment of multiple myeloma, and is approved as first-line treatment of the disease drug, the sales expected to grow from $ 1.7 billion this year, up from 2013's $ 3.6 billion. Some foreign analysts expect, Revlimid sales will boost treatment for multiple myeloma drug market growth.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Lenvatinib
MGCD-265
Pazopanib Hydrochloride
Vatalanib
Cabozantinib S-malate
Ponatinib
CP-673451
KRN-633
Cabozantinib
Regorafenib hydrochloride